摘要
目的:比较2型糖尿病(type 2 Diabetics,T2DM)患者应用脂微球前列腺素E1(Lipo PGE1)和丹参后其血浆一氧化氮(nitric oxide,NO)、内皮素(endothelin,ET)的变化。方法:66例糖尿病患者,按1999年WHO糖尿病诊断标准确认,随机分为两组:Lipo PGE1组和丹参组。两组患者临床检查均无严重心、肾、脑等并发症。ET 1 以放射免疫法测定,NO以硝酸还原法测定。结果:(1)两组T2DM患者的年龄、病程、体重指数(BMI)、收缩压、舒张压、胆固醇、甘油三酯、尿素氮、肌酐、空腹及餐后2h胰岛素、C 肽值均无显著差异。(2)两组T2DM患者用药前空腹及餐后2h血糖无显著差异,治疗2 周后两组空腹及餐后2h血糖亦无显著差异,但均比用降糖药前明显下降,有显著差异。治疗前,PEG1 组无论空腹还是餐后2 hET值均高于丹参组,而NO水平低于丹参组。经2周治疗后,丹参组ET值仅见餐后2 h有显著下降, P<0.05,余未见变化;而PEG1 组不论空腹,还是餐后2hET值均见有极显著下降, P均<0.001,且NO水平也显著升高,P均<0.05。结论:两组T2DM患者在降糖幅度相当的前提下,应用Lipo PGE1在糖尿病患者中能降低ET水平,提高NO浓度,丹参针剂未见相同结果,提示该药物不仅能直接扩张血管作用,而且还能调节ET及NO水平的间接效果,Lipo PGE1明显优于丹参针剂。
Objective: The aim studied the change of the level in ET and No after applying lipoPGE1 and DanShen on type 2 diabetics. Methods: 66 diabetics patients were confirmed according to the diagnostic criteriom issued by WHO in 1999. And the patients were divided into two groups at random.:LipoPGE1 and Dan-Shen.ET-1 determination:radilimmunoassy.NO determination:nitric-reductive assay. Results: (1)Age,during, systolic and diastolic pressure, cholesterol, triglyceride, urea nitrogen, creatinine, limosis and postcibum (2 hours later) insulin and C-peptide in the 2 groups have insignificant difference. (2)blood glucose of both limosis and postcibum(2 hours later) in 2 groups before and after administration antidiabetic medicine have insignificant change. Two week later, blood glucose declined significantly, P<0.01. ET concentration of both limosis and postcibum (2 hours later) after lipo-PGE1,administration declined significantly, P<0.001. NO level rised significantly, P<0.05.Only postcibum (2 hours later) ET after Qan- Shen administration declined significantly,P< 0.05.Conclusion:The study shows that lipoPGE1 can significantly decrease ET and increase NO Concentration, which suggests that lipoPGE1 could not only extend blood vessel directly, but also could adjust the level of ET and NO. LipoPGE1 is excellent than Dan-Sheng solution.
出处
《中国临床医学》
北大核心
2005年第2期307-309,共3页
Chinese Journal of Clinical Medicine